The syndrome of cardiac cachexia

International Journal of Cardiology

Volumn 85, Issue 1, 2002, Pages 51-66

  Anker, Stefan D ^a,b   Sharma, Rakesh ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Cachexia; Chronic heart failure; Therapy

Indexed keywords

ADRENALIN; ALDOSTERONE; AMRINONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; ETERNERCEPT; GAMMA INTERFERON; HUMAN GROWTH HORMONE; HYBRID PROTEIN; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; NORADRENALIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIMOBENDAN; PIPERANOMETOZINE; RENIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADRENALIN BLOOD LEVEL; AGE; ALDOSTERONE BLOOD LEVEL; BODY COMPOSITION; BONE TISSUE; CACHEXIA; CLINICAL TRIAL; DISEASE SEVERITY; EXERCISE; FATIGUE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; METABOLIC DISORDER; MUSCLE MASS; MUSCLE TISSUE; NEUROENDOCRINE DISEASE; NORADRENALIN BLOOD LEVEL; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SKELETAL MUSCLE;

CACHEXIA; GREECE; HEART FAILURE, CONGESTIVE; HUMANS; PROGNOSIS; SYNDROME;

EID: 0036344965     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00233-4     Document Type: Review

References (124)

1. Diseases of heart in works of Hippocrates
2. Geriatric cachexia: The role of cytokines
3. Cardiac cachexia: A syndrome with impaired survival and immune and neuroendocrine activation
4. Metropolitan height and weight tables
5. Wasting as independent risk factor for mortality in chronic heart failure
6. Prevalence and haemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy
7. Increased concentrations of tumor necrosis factor in 'cachectic' patients with severe chronic heart failure
8. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
9. Surgical treatment of patients with cardiac cachexia. An analysis of factors affecting operative mortality
10. The nutrition implications of cardiac cachexia
11. Weight loss in chronic heart failure (CHF) and the impact of treatment with ACE inhibitors - Results from the SOLVD treatment trial
12. The epidemiology of heart failure
13. Malnutrition in cardiac surgical patients
14. Nutritional support in cardiac cachexia
15. Syndromes of cardiac cachexia and the cachectic heart: Current perspective
16. The pathogenesis of cardiac cachexia
17. Gastrointestinal absorption studies in cardiac cachexia
18. Fat malabsorption in elderly patients with cardiac cachexia
19. Clinical manifestation of heart failure
20. Circulating interleukin-6 in severe heart failure
21. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
22. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure
23. Specific changes in skeletal muscle myosin heavy chains composition in cardiac failure: Differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis
24. Heart failure in rats causes changes in skeletal muscle phenotype and gene expression unrelated to locomotor activity
25. Increased resting metabolic rate in patients with congestive heart failure
26. Daily energy expenditure in free-living heart failure patients
27. Endurance training increases metabolic rate and norepinephrine appearance rate in older individuals
28. The role of inflammatory mediators in chronic heart failure: Cytokines, nitric oxide, and endothelin-1
29. The role of cytokines in disease progression in heart failure
30. Catabolism in chronic heart failure
31. Tumour necrosis factor alpha in severe congestive cardiac failure
32. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart
33. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium
34. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure
35. Endotoxin and immune activation in chronic heart failure: A prospective cohort study
36. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: The potential importance of bacterial translocation
37. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration
38. Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy
39. The endotoxin-lipoprotein hypothesis
40. Systemic inflammation in patients with heart failure
41. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production: Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute cachexia
42. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients
43. Tumour necrosis factor in chronic heart failure: A peripheral view on pathogenesis, clinical manifestations and therapeutic implications
44. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life
45. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure
46. Tumor necrosis factor increases serum leptin levels in humans
47. Hyperleptinaemia in chronic heart failure. Relationships with insulin
48. Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure
49. Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system
50. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia
51. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD)
52. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice
53. IL-6: Insights into novel biological activities
54. Loss of bone mineral in patients with cachexia due to chronic heart failure
55. Plasma cytokine parameters and mortality in patients with chronic heart failure
56. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST)
57. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors
58. Uric acid in chronic heart failure: A marker of chronic inflammation
59. Neurohormonal mechanisms involved in congestive heart failure
60. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure
61. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
62. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group
63. Genetics of cardiovascular disease
64. Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology
65. The augmentation of plasma norepinephrine response to exercise in patients with congestive heart failure
66. Relationships between plasma epinephrine, norepinephrine, dopamine and angiotensin II concentrations, renin activity, hemodynamic state and prognosis in acute heart failure
67. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism
68. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro
69. The impact of cachexia on cardiorespiratory reflex control in chronic heart failure
70. Norepinephrine turnover and energy expenditure in Pima Indian and white men
71. Free fatty acid kinetics and oxidation in congestive heart failure
72. Energy expenditure and symptom severity in men with heart failure
73. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure
74. Aldosterone and its regulation during diuresis in patients with gross congestive heart failure
75. Tumor necrosis factor and steroid metabolism in chronic heart failure: Possible relation to muscle wasting
76. Abnormalities of skeletal muscle in patients with chronic heart failure
77. Alterations of skeletal muscle in chronic heart failure
78. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure
79. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure
80. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS
81. Potassium depletion and tissue loss in chronic heart disease
82. Osteoporosis and bone morbidity in cardiac transplant recipients
83. Body composition and quality of muscle in chronic heart failure
84. Predictors of exercise capacity in chronic heart failure
85. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure
86. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation
87. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure
88. Apoptosis in skeletal muscle
89. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance
90. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure
91. Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure-effects of long-term dietary supplementation
92. Congestive heart failure: Clinical management by use of continuous nasoenteric feeding
93. Effects of physical training in chronic heart failure
94. Exercise limitation in chronic heart failure: Central role of the periphery
95. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure
96. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis
97. Inhibitors of tumor necrosis factor for rheumatoid arthritis
98. Infliximab for the treatment of fistulas in patients with Crohn's disease
99. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats
100. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro
101. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure
102. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
103. Has the time arrived to use anticytokine therapy in chronic heart failure?
104. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure
105. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: Results of a randomized study
106. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure
107. Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure
108. High- versus low-dose ACE inhibition in chronic heart failure: A double-blind, placebo-controlled study of imidapril
109. The changes in circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy
110. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure
111. Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure
112. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure
113. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
114. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor
115. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy
116. Cardiac failure responding to growth hormone
117. Treatment of end-stage cardiac failure with growth hormone
118. Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone
119. Immune and neurohormonal pathways in chronic heart failure
120. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure
121. Ventricular assist device in severe heart failure: Effects on cytokines, complement and body weight
122. The epidemiology of heart failure: The Framingham Study